, Volume 44, Issue 2, pp 334–342 | Cite as

Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma

  • Cosimo Durante
  • Alessandra Paciaroni
  • Katia Plasmati
  • Fabiana Trulli
  • Sebastiano Filetti
Mini Review


Medullary thyroid cancer (MTC) is frequently diagnosed in a locally advanced or metastatic stage, and 10-year survival rates in these cases are below 20 %. Cytotoxic chemotherapy has no significant impact on overall or progression-free survival. Vandetanib (Caprelsa®, AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors. It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012). This review, starting from the phases II and III efficacy and safety data that led to these approvals, explores important issues related to dosing, patient selection, and strategies for managing the substantial risk of toxicity associated with the drug (including life-threatening cardiac events that are the subject of a black-box warning in the United States). All these issues still remain to be defined. Vandetanib is becoming a standard of care for symptomatic, progressive, metastatic MTCs, to be used selectively in those patients who are likely to benefit from it.


Medullary thyroid carcinoma Targeted therapy Tyrosine kinase inhibitors Vandetanib RET VEGFR 



The study was supported by research Grants from The Umberto Di Mario Foundation and from the “Banca d’Italia”. The manuscript was edited by Marian Everett Kent, BSN.

Conflict of interest

S. Filetti has received fees for clinical trial participation from AstraZeneca. C. Durante, A. Paciaroni, K. Plasmati, F. Trulli declare that they have no conflict of interest.


  1. 1.
    R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, R.F. Gagel, H. Gharib, J.F. Moley, F. Pacini, M.D. Ringel, M. Schlumberger, S.A. Wells Jr, Medullary thyroid cancer: management guidelines of the American thyroid association. Thyroid 19, 565–612 (2009)PubMedCrossRefGoogle Scholar
  2. 2.
    M. Schlumberger, L. Bastholt, H. Dralle, B. Jarzab, F. Pacini, J.W.A. Smit, European thyroid association guidelines for metastatic medullary thyroid cancer. Eur. Thyroid J. 1, 5–14 (2012). doi: 10.1159/000336977 CrossRefGoogle Scholar
  3. 3.
    E. Chiefari, D. Russo, D. Giuffrida, G.A. Zampa, D. Meringolo, F. Arturi, I. Chiodini, D. Bianchi, M. Attard, V. Trischitta, R. Bruno, P. Giannasio, A. Pontecorvi, S. Filetti, Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J. Endocrinol. Invest. 21, 358–364 (1998)PubMedGoogle Scholar
  4. 4.
    M.D. Castellone, A. Verrienti, D. Magendra Rao, M. Sponziello, D. Fabbrom, M. Muthu, C. Durante, M. Maranghi, G. Damante, S. Pizzolitto, G. Costante, D. Russo, M. Santoro, S. Filetti, A novel de novo germ-line V292 M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: functional characterization. Clin. Endocrinol. (Oxf). 73, 529–534 (2010)PubMedGoogle Scholar
  5. 5.
    S. Mastroianno, M. Torlontano, A. Scillitani, L. D’Aloiso, A. Verrienti, N. Bonfitto, A. De Bonis, L. D’Agruma, L.A. Muscarella, V. Guarnieri, F. Dicembrino, M. Maranghi, C. Durante, S. Filetti, Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. Endocrine 40, 481–485 (2011)PubMedCrossRefGoogle Scholar
  6. 6.
    S. Hasani-Ranjbar, M.M. Amoli, Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome. Endocrine 42, 220–221 (2012)PubMedCrossRefGoogle Scholar
  7. 7.
    M. Santoro, F. Carlomagno, A. Romano, D.P. Bottaro, N.A. Dathan, M. Grieco, A. Fusco, G. Vecchio, B. Matoskova, M.H. Kraus, Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381–383 (1995)PubMedCrossRefGoogle Scholar
  8. 8.
    R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, E. Molinaro, L. Agate, A. Vivaldi, P. Faviana, F. Basolo, P. Miccoli, P. Berti, F. Pacini, A. Pinchera, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682–687 (2008)PubMedCrossRefGoogle Scholar
  9. 9.
    S. Leboulleux, E. Baudin, J.P. Travagli, M. Schlumberger, Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf). 61, 299–310 (2004)PubMedCrossRefGoogle Scholar
  10. 10.
    G. Costante, D. Meringolo, C. Durante, D. Bianchi, M. Nocera, S. Tumino, U. Crocetti, M. Attard, M. Maranghi, M. Torlontano, S. Filetti, Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J. Clin. Endocrinol. Metab. 92, 450–455 (2007)PubMedCrossRefGoogle Scholar
  11. 11.
    G. Costante, C. Durante, Z. Francis, M. Schlumberger, S. Filetti, Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat. Clin. Pract. Endocrinol. Metab. 5, 35–44 (2009)PubMedCrossRefGoogle Scholar
  12. 12.
    G. Costante, S. Filetti, Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 16, 49–52 (2011)PubMedCrossRefGoogle Scholar
  13. 13.
    A.L. Giraudet, D. Vanel, S. Leboulleux, A. Aupérin, C. Dromain, L. Chami, N. Ny Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, D. Hartl, J.P. Travagli, E. Baudin, M. Schlumberger, Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185–4190 (2007)PubMedCrossRefGoogle Scholar
  14. 14.
    G. Treglia, M.F. Villani, A. Giordano, V. Rufini, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42, 535–545 (2012)PubMedCrossRefGoogle Scholar
  15. 15.
    F. Orlandi, P. Caraci, A. Mussa, E. Saggiorato, G. Pancani, A. Angeli, Treatment of medullary thyroid carcinoma: an update. Endocr. Relat. Cancer 8, 135–147 (2001)PubMedCrossRefGoogle Scholar
  16. 16.
    S.I. Sherman, Targeted therapy of thyroid cancer. Biochem. Pharmacol. 80, 592–601 (2010)PubMedCrossRefGoogle Scholar
  17. 17.
    M. Schlumberger, French TUTHYREF network: targeted therapy in refractory thyroid cancer. Eur. J. Cancer 47, 328–329 (2011)CrossRefGoogle Scholar
  18. 18.
    A. Wunderlich, S. Roth, A. Ramaswamy, B.H. Greene, C. Brendel, U. Hinterseher, D.K. Bartsch, S. Hoffmann, Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine 42, 637–646 (2012)PubMedCrossRefGoogle Scholar
  19. 19.
    R. Elisei, Anaplastic thyroid cancer therapy: dream or reality? Endocrine 42, 468–470 (2012)PubMedCrossRefGoogle Scholar
  20. 20.
    C. Durante, D. Russo, A. Verrienti, S. Filetti, XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin. Investig. Drugs 20, 407–413 (2011)PubMedCrossRefGoogle Scholar
  21. 21.
    F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A.J. Ryan, G. Fontanini, A. Fusco, M. Santoro, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62, 7284–7290 (2002)PubMedGoogle Scholar
  22. 22.
    F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B.M. Veneziani, G. Fontanini, A.R. Bianco, G. Tortora, Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9, 1546–1556 (2003)PubMedGoogle Scholar
  23. 23.
    US Food And Drug Administration: news and events. FDA approves new treatment for rare form of thyroid cancer (2011), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm Accessed 21 Dec 2012
  24. 24.
    European Medicine Agency: Caprelsa. Authorisation details (2012), http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002315/human_med_001529.jsp&mid=WC0b01ac058001d124. Accessed 21 Dec 2012
  25. 25.
    S.A. Wells Jr, B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli, J. Read, P. Langmuir, A.J. Ryan, M.J. Schlumberger, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134–141 (2012)PubMedCrossRefGoogle Scholar
  26. 26.
    B.G. Robinson, L. Paz-Ares, A. Krebs, J. Vasselli, R. Haddad, Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2664–2671 (2010)PubMedCrossRefGoogle Scholar
  27. 27.
    S.A. Wells Jr, J.E. Gosnell, R.F. Gagel, J. Moley, D. Pfister, J.A. Sosa, M. Skinner, A. Krebs, J. Vasselli, M. Schlumberger, Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28, 767–772 (2010)PubMedCrossRefGoogle Scholar
  28. 28.
    US Food and Drug Administration: guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics (2007), http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf. Accessed 20 December 2012
  29. 29.
    J.C. Rambaud, R. Jian, B. Flourié, M. Hautefeuille, M. Salmeron, F. Thuillier, A. Ruskoné, C. Florent, F. Chaoui, J.J. Bernier, Pathophysiological study of diarrhoea in a patient with medullary thyroid carcinoma. Evidence against a secretory mechanism and for the role of shortened colonic transit time. Gut 29, 537–543 (1988)PubMedCrossRefGoogle Scholar
  30. 30.
    H. Liu, A. Singla, M. Ao, R.K. Gill, J. Venkatasubramanian, M.C. Rao, W.A. Alrefai, P.K. Dudeja, Calcitonin receptor-mediated CFTR activation in human intestinal epithelial cells. J. Cell Mol. Med. 15, 2697–2705 (2011)PubMedCrossRefGoogle Scholar
  31. 31.
    AstraZeneca Pharmaceuticals: vandetanib package insert (2011), http://www1.astrazeneca-us.com/pi/vandetanib.pdf. Accessed 20 Dec 2012
  32. 32.
    US Food and Drug Administration: vandetanib. risk evaluation and mitigation strategy (2011), http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM253441.pdf. Accessed 20 Dec 2012
  33. 33.
    M. Santoro, F. Carlomagno, Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 2, 42–52 (2006)PubMedCrossRefGoogle Scholar
  34. 34.
    S.N. Holden, S.G. Eckhardt, R. Basser, R. de Boer, D. Rischin, M. Green, M.A. Rosenthal, C. Wheeler, A. Barge, H.I. Hurwitz, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16, 1391–1397 (2005)PubMedCrossRefGoogle Scholar
  35. 35.
    T. Tamura, H. Minami, Y. Yamada, N. Yamamoto, T. Shimoyama, H. Murakami, A. Horiike, Y. Fujisaka, T. Shinkai, M. Tahara, K. Kawada, H. Ebi, Y. Sasaki, H. Jiang, N. Saijo, A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thorac. Oncol. 1, 1002–1009 (2006)PubMedCrossRefGoogle Scholar
  36. 36.
    ClinicalTrials.gov: to compare the effects of two doses of vandetanib in patients with advanced medullary thyroid cancer. http://clinicaltrials.gov/show/NCT01496313. Accessed 20 December 2012
  37. 37.
    N. Degrauwe, J.A. Sosa, S. Roman, H.A. Deshpande, Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin. Med. Insights Oncol. 6, 243–252 (2012)PubMedGoogle Scholar
  38. 38.
    European Medicine Agency: Caprelsa. Product information (2012) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002315/WC500123555.pdf. Accessed 21 December 2012

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Cosimo Durante
    • 1
  • Alessandra Paciaroni
    • 1
  • Katia Plasmati
    • 1
  • Fabiana Trulli
    • 1
  • Sebastiano Filetti
    • 1
  1. 1.Dipartimento di Medicina Interna e Specialità MedicheSapienza Università di RomaRomeItaly

Personalised recommendations